Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant


Cocrystal Pharma Inc's COCP COVID-19 antiviral candidate has shown antiviral potency against the omicron variant in vitro studies. 

  • The Company earlier confirmed that its protease inhibitors demonstrated broad-spectrum antiviral activity against SARS-CoV-2 and all major previously identified variants, including Delta, Alpha, Beta, and Gamma
  • Cocrystal expects to initiate Phase 1 clinical studies with its COVID-19 intranasal/pulmonary protease inhibitor CDI-45205 and an oral COVID-19 protease inhibitor as rapidly as possible.
  • CDI-45205 is one of three COVID-19 programs underway at Cocrystal. 
  • In the second COVID-19 program, the Company also plans to begin a Phase 1 study as rapidly as possible with an orally administered protease inhibitor. 
  • In the third COVID-19 program, Cocrystal uses its structure-based technology platform to discover replication inhibitors for oral administration.
  • Price Action: COCP shares are up 4.29% at $0.75 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!